Italian geographical region

Mindera Health™ announces first patient enrolled in the MATCH Study: a clinical utility evaluation of the impact of Mind.Px™ on response rates of psoriasis patients who are prescribed biologics

Retrieved on: 
Thursday, October 21, 2021

MATCH is a 16-week randomized clinical utility evaluation of the pre-treatment impact of Mind.Px on biologic drug response rates in patients suffering from psoriasis.

Key Points: 
  • MATCH is a 16-week randomized clinical utility evaluation of the pre-treatment impact of Mind.Px on biologic drug response rates in patients suffering from psoriasis.
  • According to a recent publication reporting data from the largest independent psoriasis registry (CorEvitas),1 real-world patient response rates to hyper-expensive biologics were observed to be approximately 52%.
  • These low response rates often lead to switching of therapies and massive wasted healthcare spending.
  • Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera Health scientists to take a genetic and transcriptomic snapshot of the skin.